HND 01
Alternative Names: HND-01Latest Information Update: 25 Aug 2023
At a glance
- Originator Hunan Warrant Pharmaceutical
- Class Antineoplastics; Small molecules
- Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Haematological malignancies
Most Recent Events
- 14 Apr 2023 Hunan Warrant Pharmaceutical has patents pending for use of fluoro-substituted 2-aminothiazole-5-aromatic carboxamides in USA, China, EU and Canada
- 14 Apr 2023 Preclinical trials in Haematological malignancies in China (PO)
- 14 Apr 2023 Pharmacodynamics and pharmacokinetics data from a preclinical trial in Haematological malignancies presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)